Introduction
Currently, there is no curative therapy for Alzheimer's disease (AD). The acetylcholinesterase inhibitors, such as Donepezil, antioxidants such as vitamin E, and inhibitors to NMDA excitotoxicity are clinically used in AD therapy, because they marginally delay disease progression of AD (Sano et al., 1997; Reisberg et al., 2003; Lane et al., 2004) . Because progressive neuronal loss is implicated in the development of AD-associated dementia (Mattson, 2004) , reagents that suppress neuronal death can be promising candidates for AD therapy. However, the mechanism underlying neuronal loss still remains to be elucidated.
It has been generally accepted that increased levels of toxic amyloid-␤s (A␤s) are closely related to AD pathogenesis, including neuronal cell death (for review, see Hardy and Selkoe, 2002) . In agreement, it has been reported that superphysiological concentrations of toxic A␤s cause neuronal cell death in vitro (for review, see Kawasumi et al., 2002; Niikura et al., 2002) . Moreover, several groups have reported that familial AD (FAD)-linked mutants of amyloid precursor protein (APP), presenilin 1 (PS1), and PS2 (Shastry and Giblin, 1999) cause death in multiple neuronal cell lines and primary neurons (for review, see Kawasumi et al., 2002; Niikura et al., 2002) . In addition, some antibodies recognizing the extracellular domain of APP induce death in primary neurons by activating intracellular death pathways (Rohn et al., 2000; Sudo et al., 2000 Sudo et al., , 2001 Hashimoto et al., 2003) .
Using an expression gene cloning technique called "deathtrap" screening (D'Adamio et al., 1997), we identified a novel gene encoding a 24 amino acid peptide named Humanin (HN) that suppressed neuronal death induced by any type of FAD genes thus far examined, toxic A␤ peptides, and anti-APP antibody (Hashimoto et al., 2001a Niikura et al., 2004; Nishimoto et al., 2004) . From structure/function analysis (Hashimoto et al., 2001a,b; Terashita et al., 2003) , we have obtained several HN derivatives with more potent neuroprotective activities (see Table 1 ). Among them, AGA-(C8R)HNG17, one of the most potent derivatives of HN, completely suppresses neuronal cell death by AD-relevant insults at a concentration of 10 pM in vitro.
Furthermore, Mamiya and Ukai (2001) reported that intracerebroventricular injection of S14G-HN (HNG) prevented scopolamine-induced amnesia in mice. We also found that intracerebroventricular injection of HNG reverses memory impairment of mice induced by A␤25-35 . Krejcova et al. (2004) showed recently that an HN derivative may pass through the blood-brain barrier and suppress experimentally induced behavioral abnormalities. These findings indicate that discovery of additional HN derivatives with stronger anti-AD activity both in vitro and in vivo that can pass through the bloodbrain barrier will encourage trials for clinical applications of HN.
Activity-dependent neurotrophic factor (ADNF), a nine amino acid peptide, was originally purified from conditioned medium of astrocytes (Brenneman and Gozes, 1996) . ADNF protects neurons from death induced by A␤ at extremely low concentrations such as 100 fM. In contrast to HN, however, ADNF completely loses its protective effect at or above a concentration of 1 nM (Brenneman et al., 1998) .
By taking advantage of different action properties of HN and ADNF, we have herein generated a novel hybrid peptide named Colivelin, which is composed of ADNF C-terminally fused to AGA-(C8R)HNG17. In this study, we show that Colivelin completely suppresses AD-relevant toxicity at 100 fM concentrations and keeps its neuroprotective action at or above the levels of 1 nM. We further demonstrate that Colivelin efficiently prevents memory impairment in vivo by intraperitoneal as well as intracerebroventricular administration.
Materials and Methods
Genes, polypeptides, and materials. cDNAs encoding V642I-APP and M146L-PS1 in pcDNA vectors were described previously (Hashimoto et al., 2001a,b) . Kinase-negative [dominant-negative (dn)] forms of Ca 2ϩ / calmodulin-dependent protein kinase IV (CaMKIV) and signal transducer and activator of transcription 3 (STAT3) cDNAs were described previously (Minami et al., 1996; Chiba et al., 2004) . Colivelin (SALLRSI-PAPAGASRLLLLTGEIDLP), ADNF (SALLRSIPA), and AGA-(C8R)HNG17 (PAGASRLLLLTGEIDLP) were synthesized by Asahi Techno Glass Corporation (Funabashi, Japan). Monoclonal antibody against APP (22C11), rat anti-PS1 antibody, and anti-cholineacetyl transferase (ChAT) antibody were from Chemicon (Temecula, CA). A␤1-42, A␤1-43, and A␤25-35 were purchased from Peptide Institute (Osaka, Japan).
Cells, cell death, and viability experiments. F11 cells, a hybrid of a rat embryonic day 13 primary cultured neuron and a mouse neuroblastoma N18TG2, were grown in Ham's F-12 medium (Sigma, St Louis, MO) containing 18% fetal bovine serum (FBS) (Hyclone, Logan, UT) and antibiotics, as described previously (Platika et al., 1985; Hashimoto et al., 2000) . F11 cells (7 ϫ 10 4 cells per well in a six-well plate), cultured in Ham's F-12 plus 18% FBS (HF-18%) for 12-16 h, were transfected with V642I-APP or M146L-PS1 genes by lipofection [cDNAs, 1.0 g; LipofectAMINE (Invitrogen, Carlsbad, CA), 2 l; PLUS Reagent (Invitrogen), 4 l unless otherwise mentioned] in the absence of serum for 3 h and were incubated with HF-18% for 2 h. Culture media were then changed to Ham's F-12 plus 10% FBS with or without rescue peptides (ADNF, AGA-(C8R)HNG17, and Colivelin), and cell mortality was measured at 72 h after transfection by Trypan blue exclusion assay, as described previously (Hashimoto et al., 2001a,b) . The primary culture of mouse primary cortical neurons (PCNs) was performed in poly-L-lysinecoated 96-well plates (Sumitomo Bakelite, Akita, Japan) in the absence of serum and the presence of N2 supplement, as described previously (Hashimoto et al., 2001a,b) . Prepared PCNs (5.0 ϫ 10 4 cells per well in a 96-well plate) were preincubated with or without synthetic Colivelin or AGA-(C8R)HNG17 for 16 h and treated with 25 M A␤1-43 or 20 M L-glutamate in the presence or absence of the factors for 72 h. Cell viability assays were performed as described previously (Hashimoto et al., 2001a,b) with calcein AM (Dojindo, Kumamoto, Japan) and watersoluble tetrazolium salt Cell Counting Kit 8; Dojindo) .
Immunoblot analysis. Immunoblot analysis was performed as described previously (Hashimoto et al., 2001a,b) . Lysates (20 g per lane) from cells transfected with the V642I-APP or M146L-PS1 expression vectors were subject to SDS-PAGE and were then electrically blotted to a polyvinylidene difluoride sheet. The sheet was soaked with 22C11 or anti-PS1 antibody and then with 1:5000 of horseradish peroxidaselabeled anti-mouse or anti-rat IgG antibody (Bio-Rad, Hercules, CA). The antigenic bands were visualized by ECL (Amersham Biosciences, Uppsala, Sweden).
Animals and peptide treatments (in vivo AD models). This study was conducted in accordance with the Policies on the Use of Animals and Humans in Neuroscience Research, the Society for Neuroscience, and Guideline for the Care and Use of Laboratory Animals of Keio University School of Medicine. All experimental procedures were approved by the Institutional Animal Experiment Committee at Keio University. Sevenweek-old CD-1 mice were purchased from Charles River Japan (Yokohama, Japan). Nine-week-old C57BL/6J (C57) mice were purchased from CLEA Japan (Tokyo, Japan). Animals were housed in a specific pathogen-free animal facility (23 Ϯ 1°C, 50 Ϯ 5% humidity) under a 12 h light/dark cycle (lights on 7:00 A.M. to 7:00 P.M.), as described previously (Kawasumi et al., 2004) .
To develop an AD mouse model by A␤ repetitive intracerebroventricular injection, 8-week-old CD-1 mice were implanted with cannulas in the left lateral ventricle of brain, as described previously Yamada et al., 2005) . Mice were placed in a stereotaxic surgery apparatus under anesthesia by 10% Nembutal. A C315GS-4 cannula system for mice (Plastics One, Roanoke, VA) was implanted into the left lateral ventricles under aseptic conditions through a hole drilled in the skull at the following coordinates: anteroposterior, ϩ0.3 mm; lateral, 1.0 mm; horizontal, 3.0 mm from the bregma, according to the atlas by Paxinos and Franklin (2000) . The cannula was secured with surgical glue. Ten days after cannula implantation, animals were assigned randomly to the control group, the A␤-injection group, or the A␤ plus Colivelininjection group, receiving intracerebroventricular injection of 3 l of sterile deionized distilled water (ddw), 300 pmol of A␤1-42, or 1 nmol of A␤25-35 peptide in 3 l of ddw, every other day for 3 weeks together with injection of 3 l of sterile saline or 10 pmol of Colivelin in 3 l of sterile saline once every 6 d as depicted schematically in Figure 5A . Behavioral tests were performed from 2 d after the last intracerebroventricular injection.
To develop another AD mouse model with neuronal cell death by hippocampal injection of A␤, CD-1 mice (8 weeks of age), intracerebroventricularly injected with a rescue factor into the left lateral ventricles on the previous day, were similarly placed in a stereotaxic apparatus under anesthesia by 10% Nembutal and received hippocampal injection of 3 l of sterile ddw or 300 pmol of A␤1-42 in 3 l of sterile ddw by 31 gauge needles on the next day at following coordinates: anteroposterior, ϩ1.8 mm; lateral, 1.0 mm; horizontal, 1.3 mm from the bregma. Seventy-two hours after A␤ injection, mice were killed for histological analysis of brain.
To establish a mouse model with cholinergic dysfunction, CD-1 mice (8 weeks of age) or C57 mice (10 weeks of age) were habituated in an open-field test (OF) 1 d before a Y-maze test (YM). On the YM day, the mice were injected intraperitoneally with 0.21 ml of sterile saline or the indicated amount (1.4, 7, or 35 nmol) of Colivelin in 0.21 ml of sterile saline at 30 min before YM. The mice were then injected with 0.2 ml of sterile ddw containing 20% methanol in the presence or absence of 3-quinuclidinyl benzilate (3-QNB) [17.5 ng (0.5 mg/kg body weight) for CD-1 mice; 70 ng (2.0 mg/kg body weight) for C57 mice], 15 min before YM (Krejcova et al., 2004) .
Behavioral test. OF and YM were performed as described previously (Kawasumi et al., 2004; Yamada et al., 2005) . In OF, mice were placed individually at the center of a 100 cm square gray-plastic field (with 20 cm interval black grids) and allowed to move freely for 3 min to habituate to the experimental environment. The apparatus for YM is made of three gray plastic arms (40 cm long, 12 cm high, 3 cm wide at the bottom, and 10 cm wide at the top) connected to each other at angles of 120°. Mice were placed individually at the end of an arm and allowed to explore the arms freely for 8 min. Examined parameters were (1) total arm entries and (2) spontaneous alternation percentage (SA%). SA% was defined as a ratio of the arm choices that differed from the previous two choices ("successful choices") to total choices during the run ("total entry minus two," because the first two entries could not be evaluated). For example, if a mouse made 10 entries, such as 1-2-3-2-3-1-2-3-2-1, there were five successful choices in eight total choices (10 entries minus two). Therefore, SA% in this case was 62.5%.
Immunohistochemistry. Immunohistochemical analysis was performed as described previously (Kawasumi et al., 2004; Yamada et al., 2005) . After the behavioral experiments, mice were anesthetized, perfused transcardially with PBS, and fixed by ethanol containing 5% acetic acid. Brains were embedded in paraffin, and 10 m coronal sections were prepared on New-Silane slide glasses (Muto Pure Chemicals, Tokyo, Japan). Samples were subsequently dewaxed and washed in ethanol and PBS. Immunohistochemical detection of cholinergic neurons was performed with anti-ChAT antibody (1:50 dilution; Chemicon) and visualized with the ABC method (Vectastain Elite kit; Vector Laboratories, Burlingame, CA). ChAT-immunoreactive neurons in the medial septum of five coronal sections, 10 m thickness, with a 50 m interval (ϳ0.6 -0.9 mm anterior from the bregma), were counted, and the averages of the total numbers of ChAT-immunoreactive neurons in three mice per treatment group (n ϭ 3) were compared.
Statistics. All of the experiments on neuronal cell lines described in this study were repeated at least three times with independent transfections and treatments. All values in the figures of the in vitro study indicate means Ϯ SD, and the values of the in vivo study indicate means Ϯ SEM. Statistical analysis for the in vivo experiment was performed with oneway ANOVA followed by a Fisher's PLSD, in which p Ͻ 0.05 was assessed as significant. (Table 1) , we found that (1) a Gly substitution of Ser14 (HNG) potentiates neuroprotective activity of HN by 1000-fold; (2) Ala substitutions of both Arg4 and Phe6 (AGA-HNG), disrupting sites for trypsin and chymotrypsin digestion, further augment the potency of HNG by additional 10 times; (3) the core domain of HN that mediates neuroprotective activity is the 17 amino acid sequence from Pro3 to Pro19 (HN17); (4) modulation of the free thiol group in Cys8 negatively affects the neuroprotective activity of HN and a substitution of C8R or C8K potentiates HN activity. Based on these data, we assumed that AGA-(C8R)HNG17 might result in a more potent HN derivative than AGA-HNG, the IC 50 against neurotoxicity by A␤1-43 of which is ϳ10 -100 pM (Table 1) (Hashimoto et al., 2001b . In accordance, our preliminary examination revealed that AGA-(C8R)HNG17 completely protected neurons from toxicity induced by A␤1-43 at a concentration of 10 pM, suggesting that the Arg substitution of Cys8 (C8R) augmented the potency of AGA-HNG by 10-fold.
Results

Effect of Colivelin on neuronal death by A␤1-43 in vitro
To further potentiate the rescue activity of AGA-(C8R)HNG17, we fused ADNF to it. ADNF was shown previously to suppress A␤ neurotoxicity (Brenneman and Gozes, 1996; Brenneman et al., 1998; Hashimoto et al., 2001b) . It completely suppresses A␤ neurotoxicity at a concentration of 100 fM. Unfavorably, however, ADNF loses its protective effect at concentrations higher than 1 nM. We hypothesized that N-terminal attachment of ADNF to AGA-(C8R)HNG17, which gives rise to the 26 amino acid peptide named Colivelin, may enhance the neuroprotective effect without decreasing its neuroprotective potency at higher concentrations.
To test this hypothesis, we examined the effect of the synthetic Colivelin peptide on A␤1-43-induced neuronal death, compared with that of AGA-(C8R)HNG17. We used A␤1-43 as the toxicity inducer in vitro, because A␤1-43 is the longest A␤ species detected in AD brain (Mori et al., 1992) . There is evidence showing that treatment with A␤1-43 induces death in primary cortical neurons (PCNs) with EC 50 almost comparable with that of A␤1-42 (Hashimoto et al., 2001b) . Furthermore, HN or HNG suppresses neurotoxicity by A␤1-43 with an approximate IC 50 of 1-10 M or 1-10 nM, respectively, suggesting that these IC 50 values are almost comparable with those of HN-and HNGmediated inhibition of neurotoxicity by A␤1-42 (Hashimoto et al., 2001a,b) . When PCNs were treated with 25 M A␤1-43, cell viability was reduced significantly within 72 h compared with nontreated PCNs (Fig. 1) . When PCNs were treated with 25 M A␤1-43 in the presence of 10 fM Colivelin or 1 pM AGA-C8R-HNG17, about one-half of the neurons were rescued. Full neuronal protection against A␤1-43 was obtained by treatment with either 100 fM Colivelin or 10 pM AGA-(C8R)HNG17, suggesting that Colivelin is 100 times more potent than AGA-(C8R)HNG17. Considering that HN or HNG exerts their full protection at 10 M or 10 nM, respectively (Table 1) , Colivelin is 100,000,000 or 100,000 times more potent than HN or HNG, respectively. Accordingly, we have concluded that Colivelin is a femtomolaracting bioactive peptide at least as potent as ADNF in vitro. Furthermore, Colivelin does not lose its neuroprotective activity even at higher concentrations.
Effect of Colivelin on neuronal cell death caused by V642I-APP in vitro
In our previous study (Hashimoto et al., 2001b) , HNG completely suppressed neuronal cell death induced by V642I-APP at 100 nM, whereas ADNF partially suppressed death caused by V642I-APP at concentrations from 100 fM to 10 pM. To examine the effect of Colivelin against neurotoxicity by V642I-APP, F11 cells were transfected with a V642I-APP gene-encoding vector and then treated with various concentrations of Colivelin or AGA-(C8R)HNG17 (Fig. 2 A) . Ectopic expression of V642I-APP induced death in ϳ55% of F11 neurohybrid cells, whereas no transfection or transfection with the empty vector induced death in only 10% of cells. AGA-(C8R)HNG17 treatment suppressed V642I-APP-induced neuronal cell death in a dose-dependent manner with complete neuroprotection observed at a concentration of 10 pM as it did against A␤1-43. Colivelin exhibited more potent neuroprotective effect on neuronal cell death caused by V642I-APP. Colivelin elicited full neuroprotection at a concentration of 100 fM, indicating that Colivelin has 100-fold more potent neuroprotective activity against toxicity caused by V642I-APP than AGA-(C8R)HNG17. It has been also shown that neither Colivelin nor AGA-(C8R)HNG17 loses their neuroprotective effect against V642I-induced neuronal cell death even at 100 nM, whereas ADNF has been reported to completely lose its neuroprotective effect at concentrations of 1-10 nM or more (Hashimoto et al., 2001b) . The expression levels of V642I-APP were confirmed to be unaltered by treatment with rescue factors (Fig. 2 B) .
Colivelin-mediated neuroprotection against V642I-APP through both CaMKIV and STAT3
We then asked whether Colivelin suppresses neurotoxicity induced by V642I-APP via both ADNF-and HN-mediated prosurvival pathways. We actually examined how expression of a dn form of CaMKIV or STAT3, the downstream effectors of ADNF or HN, modified the rescue function of Colivelin. To this end, we cotransfected F11 cells with the V642I-APP vector together with an expression vector encoding dnCaMKIV or dnSTAT3, or together with both vectors, and then treated cells with 100 pM ADNF, AGA-(C8R)HNG17, or Colivelin. As shown in Figure 2C , death induced by V642I-APP was suppressed completely by 100 pM AGA-(C8R)HNG17 or Colivelin and was considerably suppressed (ϳ80% of the control) by 100 pM ADNF. The neuroprotective effect of ADNF was antagonized by coexpression of dnCaMKIV but not of dnSTAT3, whereas the neuroprotective effect of AGA-(C8R)HNG17 was antagonized by coexpression of dnSTAT3 (Hashimoto et al., 2005) but not of dnCaMKIV. The neuroprotective effect of Colivelin was diminished only when both dnCaMKIV and dnSTAT3 were coexpressed simultaneously, indicating that Colivelin protects neuronal cells from death induced by V642I-APP via both ADNF-and HN-mediated prosurvival pathways.
Effect of Colivelin on neuronal cell death caused by M146L-PS1
We have reported previously that HNG completely suppresses neuronal cell death induced by ectopic overexpression of M146L-PS1 at 100 nM, whereas ADNF does not show the neuroprotective effect against M146L-PS1 even at 100 nM (Hashimoto et al., 2001b) . To examine the effect of Colivelin on neurotoxicity caused by M146L-PS1, we transfected F11 cells with a M146L-PS1 gene-encoding vector and then treated cells with various concentrations of Colivelin or AGA-(C8R)HNG17 (Fig. 3A) .
Trypan blue exclusion assay revealed that ϳ50% of neuronal cells died after transfection with the M146L-PS1 gene, whereas only 10% of cells without transfection or cells transfected with the empty vector died. Colivelin suppressed M146L-PS1-induced neuronal cell death in a dose-dependent manner with complete neuroprotection observed at a concentration of 100 fM. Although AGA-(C8R)HNG17 similarly suppressed neuronal cell death induced by M146L-PS1, 10 pM or more AGA-(C8R)HNG17 is necessary to completely suppress M146L-PS1-mediated neurotoxicity, indicating that Colivelin has 100-fold more potent neuroprotective effect than AGA-(C8R)HNG17 to suppress M146L-PS1-mediated neurotoxicity. The expression levels of M146L-PS1 were confirmed to be unaltered in the presence of neuroprotective peptides (Fig. 3B ) Given that ADNF does not suppress neuronal cell death by M146L-PS1, it is strongly suggested that neuroprotection by Colivelin is mediated only via the AGA-(C8R)HNG17 domain. If this is the case, it is highly likely that N-terminal attachment of ADNF enhances the neuroprotective effect of AGA-(C8R)HNG17. One possible mechanism underlying potentiation of HN-mediated neuroprotective activity by attachment of an N-terminal tag is that it enhances HN dimerization. Our previous study indicated that HN needs to be dimerized to be active, and N-terminal attachment of a dimerization tag (EFLIVIKS) facilitates neuroprotective activity of HN . BIAcore binding analysis (BIAcore 2000; BIAcore AB, Uppsala, Sweden), which uses the natural phenomenon of surface plasmon resonance to monitor in real time the protein-protein interaction (association/dissociation), has indicated that Colivelin also got dimerized or polymerized (data not shown). Calculated K D for Colivelin dimerization was ϳ500 times smaller than that for HN dimerization [9.41 M vs 4.79 mM, fitted to a simple 1:1 (Langmuir) binding model], on the artificial dimerization condition that Colivelin (26 amino acids) or HN (24 amino acids), immobilized onto the BIAcore dextran matrix (CM5 sensor tip) through its internal Arg and Lys residues, formed a complex with free Colivelin or free HN. In this regard, our previous pull-down study showed that His-tagged HN immobilized onto the nickel bead through its His-tag portion made a complex with FLAG-tagged HN at their concentration of 2 M, suggesting that our condition of BIAcore binding analysis underestimated K D values of Colivelin and HN, possibly because immobilization of short peptides onto the matrix through internal Arg and Lys residues interfered their association with free peptides. In addition, calculated K D for Colivelin might be further underestimated compared with HN, because Colivelin has only two Arg residues, whereas HN contains three Arg and one Lys residues, which resulted in much smaller immobilized amount of Colivelin than that of HN. In any event, based on these binding finding, we speculate that attachment of ADNF may potentiate the neuroprotective activity by accelerating peptide dimerization, although there is no direct evidence supporting this notion.
Colivelin shows protection against excitotoxicity ADNF has been originally reported to have protective activity against a variety of neurotoxic insults including excitotoxicity (NMDA), A␤, and tetrodotoxin (electrical blockade) (Brenneman and Gozes, 1996; Brenneman et al., 1998) . It is therefore highly possible that Colivelin also shows protective activity against these neurotoxic insults. To address this issue, we treated PCNs with 20 M glutamate in the presence or absence of increasing amounts of Colivelin, ADNF, or AGA-(C8R)HNG17. As shown in Figure 4 , treatment with 20 M glutamate decreased viability in PCNs. We found that although ADNF showed suppressive activity at a concentration of 10 pM, it loses its activity at a concentration of 1 nM. This unique character of ADNF was already mentioned (Brenneman and Gozes, 1996) . In contrast, AGA-(C8R)HNG17 did not attenuate neurotoxicity induced by glutamate at any concentration tested, as expected from our previous experiments (Hashimoto et al., 2001a,b) . Interestingly, Colivelin began to exhibit anti-excitotoxicity activity at a concentration of 100 fM and kept its activity even at higher concentrations (10 pM-1 nM). We thus concluded that Colivelin has neuroprotective activity not only against AD-related neurotoxicity but also against non-AD-related toxicity, probably through its ADNF moiety. In addition, it is speculated from Figure 4 that the antiexcitotoxicity activity of Colivelin appears to be enhanced by attachment of AGA-(C8R)HNG17 to ADNF.
In vivo effect of Colivelin on impairment in spatial working memory by toxic A␤s
Intracerebroventricular injection of toxic A␤ peptides has been reported to impair spatial working memory in rodents (Flood et al., 1991; Delobette et al., 1997; Yamada et al., 1999; Yamaguchi and Kawashima, 2001; Stepanichev et al., 2003b) . Although administration of A␤ into cerebral ventricles has usually been performed by a one-shot or bolus intracerebroventricular injection of a large dose of A␤, rats with dementia have been constructed successfully by continuous infusion of A␤ via an osmotic pump connected to the cerebral ventricle (Nitta et al., 1997; Yamada et 
C8R)HNG17 (100 aM,1fM,10fM, 100 fM,1pM,10pM, 100 pM,1nM,10nM, or 100 nM). As controls, mortality of cells not transfected or transfected with the pcDNA vector was measured. Seventytwo hours after transfection, cell mortality was measured by Trypan blue exclusion assay (A). Protein expression of M146L-PS1 was determined by immunoblot analysis with antibody to PS1 (B). All experiments were performed with n ϭ 3. noT, Not transfected; Vec, vector; holo, holoprotein; NTF, N-terminal fragment. Error bars represent SD.
al., 1999). We have recently developed another toxic A␤-induced mouse model of AD by using repetitive injection of A␤25-35 via an implanted cannula . Continuous administration and repetitive injection of a small dose of A␤25-35 via an implanted cannula are superior to a bolus administration of toxic A␤ in the sense that the former procedure gives rise to a brain state more resembling AD than the latter procedure. We mainly used A␤25-35, which shares with A␤1-42 the ability to selfaggregate and to induce neurotoxicity both in vitro and in vivo (Mori et al., 1992; Delobette et al., 1997) , in this animal experiment, because they are more easily solubilized in water and show neurotoxicity in vitro similar to that of A␤1-42 or A␤1-43, which are suppressed by treatment with Colivelin (data not shown).
Using this procedure, we examined the neuroprotective effect of Colivelin against A␤ toxicity in vivo. After 10 injections of 1 nmol of A␤25-35 were performed (as schematically shown in Fig.  5A ), spatial working memory of each mouse was examined in a continuous alternation version of the YM. SA%, which reflects spatial working memory, of control mice was 69.7 Ϯ 2.5%, whereas that of A␤25-35-administered mice was 56.6 Ϯ 1.8%, indicating that repetitive administration of A␤25-35 efficiently impaired spatial working memory (Fig. 5B) . In contrast, SA% of A␤25-35-administered mice treated with Colivelin at 10 pmol per 6 d was 66.4 Ϯ 1.7%, indicating that Colivelin treatment almost completely suppressed A␤25-35-mediated impairment in spatial working memory. As shown in Figure 5C , however, SA% of A␤25-35-administered mice treated with ADNF at 10 pmol per 6 d was 62.6 Ϯ 4.3%, whereas those of control and A␤25-35-adiministered mice were 70.9 Ϯ 2.3 and 58.3 Ϯ 2.2%, respectively, suggesting that ADNF treatment resulted in a marginal but statistically insignificant tendency to improve memory impairment induced by repetitive administration of A␤25-35. Colivelin treatment alone at 10 pmol per 6 d was deemed not to increase SA% in YM, as shown in Figure 5D (control, 67.3 Ϯ 3.0%;
Colivelin-treated mice, 69.9 Ϯ 2.5%). We further examined the effect of Colivelin on neurotoxicity induced by repetitive administration of A␤1-42, another toxic A␤ species detected in AD brain, which has been believed to play a critical role in the pathogenesis of AD. Ten repetitive administrations of 300 pmol of A␤1-42 similarly impaired spatial working memory; SA% in YM of A␤1-42-administered mice was 56.9 Ϯ 3.1%, whereas that of control mice was 71.4 Ϯ 2.8% (Fig. 5E) . Colivelin treatment at 100 pmol per 6 d again almost completely antagonized A␤1-42-mediated impairment in spatial working memory (SA%, 67.4 Ϯ 1.4%).
As reported in our previous study Yamada et al., 2005) , intracerebroventricular injection of A␤ downregulates the expression level of ChAT of neurons in the medial septum. We further recognized correlation between the extent of impairment in spatial working memory and the numbers of ChAT-immunoreactive neurons in the medial septum in A␤-injected mice. To confirm the neuroprotective effect of Colivelin in vivo, we performed immunohistochemical analysis of medial septa of A␤25-35-administered mice with or without Colivelin treatment. Brain sections of mice were immunohistochemically stained with anti-ChAT antibody, and the numbers of immunoreactive neurons in medial septa were compared (Fig.  6 A-C) . We observed a significant decrease in the numbers of ChAT-immunoreactive neurons in medial septa of A␤25-35-injected mice (188.7 Ϯ 40.2 ChAT-immunoreactive neurons) compared with the control mice (517.7 Ϯ 17.7) (Fig. 6 D) . Consistent with the results of SA% in YM, Colivelin treatment significantly increased the number of immunoreactive neurons, which were downregulated by repetitive A␤25-35 injection, to a comparable with that of control (445.7 Ϯ 35.0).
In vivo effect of Colivelin on hippocampal neuronal death by A␤1-42
Multiple groups have reported that intracerebral or hippocampal injection of A␤ causes neuronal degeneration in rodents (Frautschy et al., 1991; Kowall et al., 1992; Miguel-Hidalgo and Cacabelos, 1998; Stephan et al., 2001; Stepanichev et al., 2003a; Ryu et al., 2004) . To examine the in vivo neuroprotective effect of Colivelin on neuronal death by A␤1-42, we performed hippocampal injection of 300 pmol of A␤1-42 into the CA1 region 1 d after intracerebroventricular injection of neuroprotective factors. Seventy-two hours after hippocampal injection, mice were killed to prepare paraffin-embedded hippocampal sections, which were subsequently stained with cresyl violet. As shown in Figure 7 , hippocampal injection of A␤1-42 resulted in robust neuronal loss in the CA1 region, whereas there was no significant neuronal loss in saline-injected control mice. Intracerebroventricular injection of 100 pmol of Colivelin before hippocampal A␤ injection completely protected neurons from toxicity induced by A␤1-42 injection. On the other hand, neither administration of 100 pmol of AGA-(C8R)HNG17 nor administration of a mixture of ADNF and AGA-(C8R)HNG17 at the same dosage exhibited as potent a neuroprotective effect as Colivelin, suggesting that fusion of ADNF and AGA-(C8R)HNG17 gives rise to a much superior neuroprotective peptide over its either parent.
Protection against cholinotoxin-induced amnesia by intraperitoneal injection of Colivelin
Dysfunction of the cholinergic system in the CNS, including the medial septal nucleus and the nucleus basalis of Mynert, is implicated in the development of cognitive impairment of AD (Bartus et al., 1982; Coyle et al., 1983) . In accordance, administration of several cholinotoxins, including scopolamine, 3-QNB, and ethylcholine aziridium (AF64A), was reported to induce memory impairment in rodents and humans (Fisher et al., 1989; Ebert and Kirch, 1998; Gozes et al., 2000; Krejcova et al., 2004) . Consequently, mice treated with these cholinotoxins are also used widely as AD models, in addition to A␤-injected or genetically engineered models. We examined the effect of intraperitoneal injection of 7 nmol of Colivelin on spatial working memory impairment caused by intraperitoneally administered 3-QNB (Fig.  8 A) . SA% in YM of control C57 mice was 60.9 Ϯ 3.7%. In agreement with the previous findings (Krejcova et al., 2004) , intraperitoneally administered 3-QNB at 2.0 mg/kg elicited potent neurotoxicity in C57 mice, and SA% of 3-QNB-treated mice was 38.3 Ϯ 3.5%. Four mice of a total of eight were excluded from the test because they did not enter more than three arms in this particular experiment. In contrast, SA% of 3-QNB-administered mice preinjected intraperitoneally with 7 nmol of Colivelin was 52.4 Ϯ 3.1%. Only two mice of a total of eleven were excluded from the test. This result suggests that intraperitoneally administered Colivelin passes through the blood-brain barrier and significantly attenuates cholinotoxin-induced amnesia. To see whether there is dose dependency in the neuroprotective effect by intraperitoneal injection of Colivelin, we intraperitoneally injected 3-QNBtreated mice with three different doses of Colivelin, using CD-1 mice, which may be less sensitive to the intraperitoneal procedure than C57 mice. As shown in Figure 8 B, Colivelin showed anticholinotoxicity activity in a dose-response manner with maximal protection at a dose of 7 nmol. In this experiment, no mice were excluded from the analysis because of 3-QNB-induced immobility observed in C57 mice. We further examined the effect of intraperitoneally administered Colivelin in comparison with that of HNG. As shown in Figure 8C , CD-1 mice with 3-QNB treatment resulted in deterioration of SA% (50.6 Ϯ 2.7%) compared with control mice (68.2 Ϯ 1.6%). Intraperitoneal injection of Colivelin again significantly attenuated 3-QNB-induced spatial working memory deficits (59.5 Ϯ 2.3%) to a greater extent than that of HNG (54.8 Ϯ 2.1%), indicating that Colivelin is superior to HNG even in vivo.
Discussion
We have herein shown that a hybrid peptide composed of AGA-(C8R)HNG17 C-terminally attached with ADNF is the most potent derivative of HN so far developed. Colivelin completely suppressed neuronal cell death induced by 25 M A␤1-43 and overexpression of V642I-APP or M146L-PS1 at a concentration as low as 100 fM in vitro. Furthermore, HN does not lose its anti-AD activity at its higher concentrations, in contrast to ADNF.
ADNF itself has a neuroprotective effect on multiple types of toxicities including A␤ neurotoxicity, electrical blockade with tetrodotoxin, excitotoxicity (NMDA), and oxidative stress (Brenneman and Gozes, 1996; Brenneman et al., 1998 ). ADNF completely suppresses A␤ neurotoxicity at a concentration as low as 100 fM in vitro. One of unfavorable characteristics of ADNF, however, is that it completely loses its protective effect at or above the nanomolar levels. On the other hand, AGA-(C8R)HNG17 displays its complete neuroprotective effect at concentrations of 10 pM or more but does not lose its neuroprotective activity at higher concentrations. As shown in Figure 2C , Colivelin simultaneously activates two distinct prosurvival pathways, which are triggered by ADNF and HN. Accordingly, it is likely that neuroprotection against A␤ at low concentrations (100 fM-10 pM) of Colivelin might be primarily mediated by ADNF, whereas neuroprotection against A␤ at higher concentrations (10 nM) of Colivelin might be mainly mediated by AGA-(C8R)HNG17. In addition, as shown in Figure 3 , it is highly likely that N-terminal attachment of ADNF promotes the neuroprotective effect of AGA-(C8R)HNG17.
It is further suggested that via the ADNF-mediated pathway, Colivelin can suppress multiple types of toxicity other than neurotoxicity induced by ADrelevant insults. For instance, as shown in Figure 4 , Colivelin attenuates excitotoxicity induced by glutamate, although HN is reported to be ineffective against glutamate-induced neurotoxicity (Hashimoto et al., 2001b) . Furthermore, we have found recently that the anti-ALS effect in vivo of Colivelin is stronger than ADNF, possibly because attachment of AGA-(C8R)HNG17 stabilizes the peptide in vivo. Consequently, intracerebroventricular administration of Colivelin prolongs survival of ALS model mice (T. Chiba, M. Yamada, and M. Matsuoka, unpublished observation).
In the rescue experiments with PCNs treated with A␤s, cells were necessarily preincubated with HN or its derivative for 16 h before addition of A␤s. Such long preincubation appears to result in protein synthesis. This fact is in accordance with recently characterized signal transduction pathways mediated by the HN receptor on the cell membrane that is connected with activation of a transcription factor, STAT3 (Hashimoto et al., 2005) .
We have reported that HN is secreted from cells, and from outside cells it binds to the membrane receptor and activates a prosurvival pathway linked to STAT 3 activation (Hashimoto et al., 2001a (Hashimoto et al., ,b, 2005 Yamagishi et al., 2003) . Independently, Guo et al. (2003) reported that HN intracellularly inhibits Bax-mediated apoptosis by binding to Bax. Together, it could be hypothesized that HN acts as an anti-celldeath factor by two ways of action. However, it remains to be addressed whether the latter mechanism is really involved in neuroprotective activity by HN or Colivelin.
We also confirmed the potent neuroprotective effect of Colivelin on ADrelevant insults in vivo. To examine this effect, we used three types of models: the repetitive A␤ intracerebroventricular model, the 3-QNB model, and the A␤ hippocampal injection model. We have recognized that repeated intracerebroventricular administration of toxic A␤ did not cause apparent death in hippocampal neurons including cholinergic neurons . The first two models were used primarily to detect impairment in spatial working memory; the A␤ hippocampal injection model was used to histologically examine neuronal cell death in the CA1 region. Therefore, the first two recapitulate the functional abnormality of AD, and the third reproduces neuronal cell death, one of the most important pathological hallmarks of AD. Using repetitive A␤ intracerebroventricular model mice, we have demonstrated that Colivelin has a potent in vivo neuroprotective effect on A␤-induced memory dysfunction. Based on the finding that ADNF in the same amount as Colivelin only showed a slight Figure 8 . In vivo effect of intraperitoneal injection of Colivelin on 3-QNB-induced amnesia. A, SA% of C57 mice with 3-QNB treatment (70 ng) in the presence or absence of intraperitoneal preinjection of Colivelin (7 nmol) were compared. B, SA% of CD-1 mice with 3-QNB treatment (17.5 ng) in the presence of intraperitoneal preinjection of increasing doses of Colivelin (1.4, 7, and 35 nmol). C, SA% of CD-1 mice with 3-QNB treatment (17.5 ng) in the presence or absence of intraperitoneal injection of Colivelin or HNG (7 nmol) were compared. Data are shown as means Ϯ SEM. Statistical analyses were performed by one-way ANOVA followed by Fisher's PLSD (*p Ͻ 0.05; **p Ͻ 0.01). tendency to compromise A␤ neurotoxicity, we have concluded that Colivelin has a more potent neuroprotective effect than ADNF in vivo. We reported in our previous study that intracerebroventricular injection of HNG at 50 pmol or 1 nmol per week for 3 weeks attenuated toxicity induced by single intracerebroventricular injection of A␤25-35 . Mamiya and Ukai (2001) also reported that intracerebroventricular injection of 1 nmol of HNG attenuated spatial working memory impairment induced by scopolamine. Our present study has shown clearly that smaller amounts of Colivelin suppress impairment in spatial working memory induced by repetitive intracerebroventricular injection of A␤25-35 and AD-relevant A␤1-42, demonstrating a more potent neuroprotective action of Colivelin than HNG in vivo. Using A␤ hippocampal injection models, we further demonstrated that focal neuronal cell death was induced by injection of 300 pmol of A␤1-42 around A␤-injected areas in the CA1 region of hippocampus. Intracerebroventricular pretreatment of Colivelin at 100 pmol almost completely antagonized A␤-mediated neuronal death in vivo, as observed in vitro, whereas neither the same amount of AGA-(C8R)HNG alone nor administration of a mixture of ADNF and AGA-(C8R)HNG17 completely suppressed neuronal death caused by A␤1-42 (Fig. 7) . It is notable that administration of a mixture of ADNF and AGA-(C8R)HNG17 did not exhibit as potent a neuroprotective effect in vivo as Colivelin, suggesting that fusion of two peptides gives rise to additional advantages, even in vivo.
Using the 3-QNB model, we further examined the effect of intraperitoneally administered Colivelin on impairment in spatial working memory induced by 3-QNB. In agreement with the previous report (Krejcova et al., 2004) , we observed a suppressive effect of intraperitoneal injection of Colivelin on memory impairment by 3-QNB in both C57 and CD-1 mice. However, Colivelin did not completely suppress 3-QNB-induced neurotoxicity. Possible reasons are, first, that 3-QNB has additional toxic effects except for the antagonistic effect on muscarinic acetylcholine receptor that is not blocked by treatment with HN derivatives and/or second, that the intraperitoneally administered dose of Colivelin was not sufficient to suppress neuronal dysfunction by 3-QNB. In any event, it is apparent that Colivelin exhibited a more potent neuroprotective effect than HNG even when it was administered intraperitoneally.
In summary, this study has characterized the most potent HN derivative named Colivelin, composed of ADNF and AGA-(C8R)HNG17. Its potent anti-AD activity, both in vitro and in vivo, will encourage clinical application of Colivelin as an anti-AD candidate drug to suppress both AD-related neuronal cell death and dysfunction of the memory system.
